Baxalta Now Part Of Shire
Clinical trials sponsored by Baxalta Now Part Of Shire, explained in plain language.
-
One-Shot gene therapy could tame hemophilia b bleeding
Disease control OngoingThis study tests a single intravenous dose of gene therapy (AskBio009) in up to 30 adults with hemophilia B, a bleeding disorder. The therapy delivers a working copy of the factor IX gene to help the body produce its own clotting factor. The main goal is to check safety, but rese…
Phase: PHASE1, PHASE2 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated May 26, 2026 10:53 UTC
-
Hemophilia a drug safety checked in long-term real-world study
Disease control OngoingThis study looks at the long-term safety of the medicine ADYNOVI/ADYNOVATE in people with hemophilia A. It involves 207 participants who already use this drug to prevent bleeding. The main goal is to track any side effects, especially those that might affect the kidneys, liver, o…
Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated May 22, 2026 14:04 UTC